Table 1.
Human Papillomavirus Genotypes Distribution in Genital Infection and Cervical Cancer in Iran
| Author/Year | Region | HPV Detection Method | Number /Type of Study | HPV Positive/ HPV Genotypes /Co infection |
|---|---|---|---|---|
| Hamkar et al., 2002 [13] | Mazandaran/ Iran | Home-brew PCR | 100/ Routine Checkups & Cervical Cancer | 78.6 % / HPV 16,18,31,33,6,11 / HPV16/18: 1.51%, HPV31/33: 16.24%, HPV6/11: 4.18% |
| Mortazavi et al., 2002 [14] | Tehran/Irn | In Situ Hybridization & Home Brew PCR (Triplex PCR 16,18,33) | 100/ FFPE Cervical Cancer | 82% / HPV 16,18,3 / Not Mentioned |
| Hamkar et al., 2003 [15] | Mazandaran/ Iran | Home-brew PCR & In Situ Hybridization | 254/ Routine checkups & Cervical Cancer | 44.48% / HPV 16,18,6,11,31,33/ Not Mentioned |
| Farjadian et al.,2003 [16] | Shiraz/ Iran | Home-brew PCR ( Duplex PCR 16&18) |
101/ FFPE Cervical Cancer | 87.12% / HPV16,18 / Not Mentioned |
| Zandi et al., 2010 [17] | Bushehr/ Iran | Home Brew PCR GP5/GP6 & Sequencing | 200/ Routine Checkups | 5.5% / HPV 16,18,53 / Not Mentioned |
| Safaie et al., 2010 [18] | Shiraz/ Iran | Home-brew PCR ( Duplex PCR 16&18) |
402/ Routine Checkups | 5.47% / HPV 16 / Not Mentioned |
| Shahramian et al., 2011 [19] | Zabol/ Iran | Home Brew PCR GP5/GP6 - MY09/MY11 & Duplex PCR 16&18 |
402/ Routine Checkups | 21.39% / HPV 16 ,18 / Not Mentioned |
| Jaberipour et al.,2011 [20] | Shiraz/ Iran | Real-time for 16, 18, 33,52 (Primer Design®) |
100/ Tissue, Biopsy, Blood & Genital Wart | 19% / HPV 16,18 / 2% |
| Jaberipour et al.,2011 [21] | Shiraz/ Iran | Real-time for 16, 18, 33,52 (Primer Design®) |
79/ Genital Wart | 16.45% / HPV 16,18 / 1.3 % |
| Moradi et al.,2011 [22] | Gorgan/ Iran | Home Brew PCR GP5/GP6- MY09/MY11 & Duplex PCR 16&18 |
308/ Routine Checkups | 24.67% / HPV 16,18 / Not Mentioned |
| Allameh et al.,2011 [23] | Isfahan/ Iran | Home Brew PCR GP5/GP6 & Primer Specific PCR HPV 6,11,16,18 | 130/ Abnormal Cytology | 24.67% / HPV 16,18,6,11 / 83.1 % |
| Shahsia et al.,2011 [24] | Tehran/ Iran | Home Brew PCR GP5/GP6 & Sequencing | 87/ FFPE Cervical Cancer | 79.31% / HPV 16,18,31,45/ Not Mentioned |
| Khodakarami et al.,2011 [25] | Tehran/ Iran | Home Brew PCR GP5/GP6 | 825/ Normal & Abnormal Cytology | 7.75% / HPV 16,18,31,39,45,51,52,56,58,59, 73,6,32,40,42,5466,67/ ≥3% |
| Eghbali et al.,2012 [26] | Bushehr/ Iran | Home Brew PCR GP5/GP6 & LiPA | 799/ Routine Checkups | 0.62% / HPV 16,18,31,33,51,56,66 / 0.25 % |
| Hamidifard et al.,2012 [27] | Ahvaz/ Iran | Home Brew PCR GP5/GP6 & Sequencing | 60/ FFPE (Normal & Abnormal) | 13.33% / HPV 16,18,6,11/ Not Mentioned |
| Moeini et al.,2012 [28] | Tehran/ Iran | Home Brew PCR MY09/MY11 | 96 / FFPE Cervical Cancer | 18.75% / HPV Positive/ Not Mentioned |
| Haghshenas et al., 2013[29] | Sari/ Iran | Amplisens® | 98/ FFPE Cervical Cancer | 79.59% / HPV 16,18,45,39 / Not Mentioned |
| Shafaghi et al., 2013 [30] | Tehran/ Iran | Home Brew Nested PCR MY09/MY11, GP5/GP6 & RFLP | 851/ Routine Checkups | 30.08% / HPV16,18,31,33,35,39,45,51,52,56,58,59,66,68,6,11,42,43,44 / 29.1% |
| Mobinikeshe et al.,2013 [31] | 11 Province/ Iran | Home Brew Nested PCR Only HPV 16 |
108/ Routine Checkups | 25% / HPV16 / Not Mentioned |
| Shanehsazzadeh et al., 2014 [32] | Isfahan/ Iran | Home Brew PCR GP5/GP6 & Duplex PCR 16&18 | 156/ FFPE Cervical Cancer | 58.97% / HPV 16,18 / 3.85 % |
| Pouryasin et al., 2014 [33] |
Tehran/ Iran | LiPA | 80/ HPV Positive Patients | 100% / 6,16,53,18,52,39,66,11,31,33,35,45,56, 58, 68, 82,54,44,69/71 / Co-infection 50% 2 types : 31.1%, 3 types: 8.7%, 4 type: 6.3%, 5 types : 2.5%, 6 type: 1.2% |
| Mirzaei-Kashani et al., 2014 [34] | Isfahan/ Iran | Home Brew Nested PCR MY09/MY11, GP5/GP6 | 122/ FFPE Cervical Cancer | 76.39% / HPV Positive / Not Mentioned |
| Sohrabi et al., 2014 [12] |
Tehran/ Iran | Home Brew TaqMan Real Time PCR | 112/ Routine Checkups & Cervical Cancer | 93.75% / HPV 6,11,16,18,31,33,35,39,45,51,52,56, 58,59,68 / ≤12.4 % |
| Mohesni-Mehran et al., 2015 [35] | Rasht/ Iran | Home Brew PCR GP5/GP6 | 103/ Routine Checkups & Abnormal Cytology | 4.9 %/ HPV Positive/ Not Mentioned |